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Warm antibody hemolytic anemia is the
most common form of autoimmune he-
molytic anemia. When therapy is needed,
corticosteroids remain the cornerstone
of initial treatment but are able to cure
only aminority of patients (<20%). Splenec-
tomy is usually proposed when a second-
line therapy is needed. This classical
approach is now challenged by the use
of rituximab both as second-line and as
first-line therapy. Second-line treatment
with rituximab leads to response rates sim-
ilar to splenectomy (∼70%), but rituximab-
induced responses seem less sustained.
However, additional courses of rituximab
are most often followed by responses, at
the price of reasonable toxicity. In some
major European centers, rituximab is
now the preferred second-line therapy of
warmantibody hemolytic anemia in adults,
although no prospective study convinc-
ingly supports this attitude. A recent
randomized study strongly suggests
that in first-line treatment, rituximab
combined with steroids is superior to
monotherapywith steroids. If this finding
is confirmed, rituximab will emerge as a
major component of the management of
warm antibody hemolytic anemia not only
after relapse but as soon as treatment is
needed. (Blood. 2015;125(21):3223-3229)
Introduction
Autoimmune hemolytic anemia (AIHA) is an uncommon acquired
disorder in which autoantibodies directed against self-red blood cell
membrane antigens lead to their accelerated destruction. The esti-
mated incidence of AIHA in adults is 0.8-3 per 100 000 per year,
with amortality rate of 11%.1 The diagnosis is based on the presence
of a hemolytic anemia with a positive direct antiglobulin test (or
Coombs test) and on the absence of any other hereditary or acquired
cause of hemolysis, although direct antiglobulin test-negative cases
are not quite uncommon (5% of 308 cases of AIHA recently re-
ported by the Gruppo Italiano Malattie EMatologiche dell’Adulto
[GIMEMA]).2 Among AIHAs, AIHA caused by warm antibody
(wAIHA) accounts for 70% to 80% of all cases in adults and for
almost 90% of the cases in children.3 wAIHA can be either primary
(or idiopathic) or associated in at least half of the cases with an
underlying disease (lymphoproliferative disorder, 20%; autoimmune
disease, 20%; infections; and tumors) and, in the latter case, is
classiﬁed as secondary wAIHA.3
Themanagement ofwAIHAhas long been and still remainsmainly
empirical or based on retrospective uncontrolled studies.1,4,5
When therapy is necessary, corticosteroids are usually given asﬁrst-
line treatment. A response to corticosteroids is observed in 70% to 85%
of the cases and generally occurs within the ﬁrst 3 weeks of treatment.3
However, only one third of the patients remain in remission without
therapy 1 year later and ,20% are cured by steroids alone. The
proportion of patients needing second-line therapy has been poorly
assessed, with ﬁgures ranging from 20% to 30% up to 56%.1,2 In-
travenous immunoglobulins, cyclosporin, mycophenolate mofetil,
azathioprine, cyclophosphamide, and emergency treatment of the
underlyingdisorder should all be considered in the rare life-threatening
wAIHAs and/or in the absence of response to corticosteroids.6,7
Splenectomyhas long been themain and preferred second-line option,
with a sustained response rate of; 60% to 70%, although secondary
cases seem less responsive than idiopathic forms.8,9 The cure rate is
estimated to be 20%. The role and best timing of splenectomy are
currently controversial as alternatives such as rituximab are now
available.
How does rituximab work?
Rituximab is a chimeric human/murine monoclonal antibody directed
against the CD20 antigen, expressed on the surface of precursor and
mature B lymphocytes, but not on hematopoietic stem cells, very early
B cells, and mature plasma cells (Figure 1). This selected target pop-
ulation explains the low toxicity proﬁle of the molecule.10
In addition to their role in production and secretion of autoanti-
bodies, B cells also contribute to the pathogenic process in immune-
mediated disorders by producing inﬂammatory cytokines and by acting
as antigen-presenting cells, leading toT-cell activation. Recentﬁndings
have also pointed to amajor roleof different T-cell subtypes in the onset
and progression of different autoimmune disorders, especially CD41
CD251FOXP3 regulatory T cells (Tregs). These Tregs are key players
in the process of immunologic self-tolerance, with decreased levels
being associated with autoreactivity and deterioration of autoimmune
disorders, includingAIHA.11Another important T-cell player involved
in the autoreactive process is the Th17 cell, a subset of CD41 T helper
cells. By secretion of interleukin-17, these cells also contribute to the
autoimmune reaction.12Finally, in patientswith autoimmunedisorders,
there is a disturbed proinﬂammatory Th1/anti-inﬂammatory Th2 bal-
ance in favor of Th1 lymphocytes.13
By binding toCD20, rituximab has been shown to induce apoptosis
of (bothmalignant and normal) CD20-positive B lymphocytes through
different mechanisms, including antibody-dependent cell-mediated
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cytotoxicity, complement-dependent cytotoxicity, direct apoptotic
activity, disturbed T-cell activation, and possible vaccinal effects.14
The latter effect, which has been demonstrated in follicular lym-
phoma patients, is based on the development of a speciﬁc cellular
response.15 In patients treated for wAIHA, this effect has not been
demonstrated, although the observation of delayed responses
with rituximab may be partially explained by this effect. Initially
it was hypothesized that B-cell depletion was responsible for the
impressive response rates in a large proportion of patients pre-
senting with different immune-mediated disorders. However, it
soon became clear that B-cell depletion occurs in all patients treated
with rituximab, whether they responded or not, requiring additional
explanations.16 The effect of rituximab on the different T-cell
subsets in immune-mediated hematologic disorders have been
mainly reported in patients presenting with immune thrombocyto-
penia (ITP). In this disorder, characterized by the immune mediated
destruction of platelets, rituximab has shown to be associated with
a lasting and pronounced T-cell suppressive polarization, including
elevation of Tregs and restoration of the Th1/Th2 balance, but only
in responding patients.17-19 In addition, rituximab also induces
downregulation of CD40 and CD80 on B cells, leading to further
disturbed T-cell activation.20,21 Finally, it has been suggested that
rituximab may lead to macrophage Fc-receptor blockade by
rituximab-opsonized B cells and hence reduction of platelet de-
struction in the spleen, a mechanism referred to as the “immune
complex decoy hypothesis.”22 Barcellini et al23 investigated
the association between the clinical response to low-dose rituximab
and cytokine production in patients with (bothwarm and cold types)
AIHA. In this study, the authors found a decrease in interferon-g,
interleukin-12, and tumor necrosis factor-a (all TH1 cytokines)
levels in patients responding to rituximab, consistent with restora-
tion of the Th1/Th2 balance.
Can we anticipate which patients will be
responsive to rituximab?
Several case reports and retrospective series have shown that treatment
of patients with relapsed/refractory wAIHA with rituximab is asso-
ciated with overall response rates of about 70% to 80%, with a median
duration of response of;1 to 2 years (Table 1). However, similar to the
use of steroids in this disorder, relapses are frequent.24 Median time to
response is 4 to 6 weeks following the ﬁrst rituximab dose, although
responses within the ﬁrst week (probably due to the immune complex
decoy hypothesis) and after 3 months are not uncommon. A major
drawback of these conclusions is the fact that comparison between
different series is very difﬁcult given the huge heterogeneity in criteria
used to deﬁne responses.
In 5 studies that included $30 patients, factors predicting for a
response to rituximabwere analyzed.2,23,25-27 In 4 studies, responses in
wAIHA and cold agglutinin disease (CAD) were compared and were
Figure 1. Mechanisms of action of rituximab (reproduced from Dierickx et al24 with permission).
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found superior in wAIHA in 3 studies,2,23,25 whereas no difference in
response rate was observed in the study of Peñalver et al. In the
GIMEMA study, this difference was noted in patients given low-dose
rituximab, whereas no signiﬁcant difference in response ratewas found
after treatment with a conventional dose of rituximab.2 In addition, in
the same study, an increased response rate was associated with young
age and with a shorter interval between treatment and diagnosis only
in patients given low-dose rituximab. In GIMEMA, patients were
given a conventional dose of rituximab, and in the 4 other publica-
tions, a difference in outcome (generally in response rate) could not
be identiﬁed with respect to age, sex, duration of the disease, pre-
vious splenectomy, presence of an underlying disorder, association
of rituximab with other immunosuppressive drugs, or response to
previous therapies.
Thus, at this time, no validated pretreatment clinical or biochemi-
cal parameter consistently predicts outcome following rituximab treat-
ment, except for a better response rate in wAIHA compared with CAD
and, possibly, younger age and early treatment in patients given low-
dose rituximab.2,22 In a recently published meta-analysis of 21 studies
younger age and wAIHA were conﬁrmed as predictive factors for
overall and complete response rate following rituximab therapy.28
Rituximab in some special presentations
of wAIHA
Chronic lymphocytic leukemia-associated AIHA
Autoimmune cytopenias are well-known complications of chronic
lymphocytic leukemia (CLL), AIHA being the most common with an
estimated incidence of up to 10%.29 CLL patients with AIHA seem to
have a better prognosis compared with those with advanced stage
(Binet C) showing anemia due to bone marrow inﬁltration, but have
a worse survival compared with early stage (Binet A) patients without
anemia.30,31 For patients diagnosedwithCLL-associatedwAIHA,ﬁrst-
line therapy consists of steroids, similar to primary wAIHA. In case of
failure, these patients may respond to rituximab-containing immuno-
chemotherapy, with RCD (rituximab, cyclophosphamide, and dexa-
methasone) being the most successful regimen leading to overall
response rates of 90% and a complete response rate up to 60%, with
durable responses in a signiﬁcant proportion of patients.32,33 Recently
Quinquenel et al34 reported on 26 patients with CLL-associated AIHA
treated with a combination of bendamustine and rituximab, leading to
overall response rates of 81%, with a median duration of response of
28.3 months. Interestingly, half of the patients were previously treated
with RCD, making comparison between both regimens possible. In
the majority of cases, bendamustine and rituximab treatment was as-
sociated with a longer response duration compared with prior RCD
treatment.
Evans syndrome
Evans syndrome (ES) is characterized by the sequential or simulta-
neous occurrence of AIHA and ITP. Treatment with rituximab is also
efﬁcacious in patients with ES, as shown by a French retrospective
study: of 11 patients, 9 responded (5 complete and 4 partial),35 whereas
in 8 patients, CLL-associated ES combination treatment with RCD
induced 6 responses.33
Primary immunodeficiency-associated AIHA
Autoimmune cytopenias are a common feature in many primary
immunodeﬁciencies, including common variable immunodeﬁciency.
Treatment with rituximab in common variable immunodeﬁciency-
associated autoimmune cytopenias was evaluated in a recent French
retrospectivemulticenter study, where it was given to 33 (mainly adult)
often heavily pretreated patients including 5 patients with AIHA and 7
with ES (no information on type of AIHA available). In this setting,
rituximab appeared to be highly effective (4 of 5 complete responses in
AIHA) and relatively safe, especially taking into account the vulner-
ability to infections in this population.36
AIHA in patients with systemic autoimmune disorders
Ina recentlypublishedFrenchsinglecenter study including60caseswith
wAIHA, 13%of all and 21%of secondary caseswere associatedwith an
underlying autoimmune disorder, mainly systemic lupus erythematosus
(SLE).37 It has been estimated that AIHA occurs in up to 10% of SLE
patients during their disease course, with most AIHA cases being
diagnosed at the onset of the disease.38 Several trialswith rituximab have
been conducted in patients with SLE, showing signiﬁcant improvement
in hematologic complications, although 2 randomized trials failed
to demonstrate a signiﬁcant activity of rituximab on the underlying
autoimmune disorder with or without renal involvement.39
Transplantation-associated AIHA
Allogeneic hematopoietic stem cell transplantation (HSCT) is asso-
ciated with a high rate of complications, mainly including infections
Table 1. Clinical evidence evaluating the efficacy of rituximab in the treatment of wAIHA
First author (year) Study type wAIHA type Setting Number of patients Age (years)* Previous Splx ORR/CRR Response duration
Zecca (2003) P M R/R 14 0-14 13 87/NR 7-271
Narat (2005) R M R/R 11 18-81 5 64/27 2-20
D’Arena (2007) R PW R/R 11 23-81 9 100/73 1-961
Bussone (2009) R M R/R 27 15-81 22 93/30 NR
Dierickx (2009) R M R/R 36 1-87 19 79/47 1-year PFS 5 72%
Pen˜alver (2010) R M R/R 27 20-86 13 77/61 61(if CR)
Barcellini (2013) P PW F;R/R 18 19-79 0 90/60 361
Maung (2013) R M R/R 34 14-83 3 71/26 6-60
Birgens (2013) P M F 32 35-90 0 75% CR at 12 mo 361
Roumier (2014) R M R/R 25 30-76 NR 80/NR 50% relapse after 14 6 8 months
Barcellini (2014) R PW R/R 32 0-95 NR 81/53 NR
This table excludes series describing the use of rituximab in patients with only secondary wAIHA. CR, compete response; CRR, complete response rate; F, frontline; M,
mixed primary and secondary wAIHA; NR, not reported; ORR, overall response rate; P, prospective; PW, primary wAIHA; PFS, progression-free survival; R, retrospective; R/
R, relapsed or refractory; splx, splenectomy; wAIHA, warm type autoimmune hemolytic anemia.
*Age of all included patients (warm 1 cold type).
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and graft-versus-host disease. The latter complication refers to an
immunologic response, targeting cells and organs of the patient and
explains the alloimmune cytopenias, including hemolytic anemia fol-
lowing allogeneic HSCT. On the other hand, lymphocyte depletion of
the donor graft (to prevent graft-versus-host disease) can also lead to,
probably due to removal of CD41CD251FOXP3 Tregs, autoreactive
hemolytic anemia. In addition, de novo autoimmune cytopenias are
also observed following autologousHSCT.40The incidence of immune
cytopenias following allogeneic HSCT, including cord blood trans-
plantation, is estimated to be 2% to 6%. In a recently published large
retrospective analysis from the London King’s College Hospital
including 533 adult patients, overall incidence of allogeneic HSCT-
associated (mainly warm type) AIHAwas 3.6%. Response to ﬁrst-line
treatment with steroids was very poor (only 10%), requiring further
immunosuppressive treatment in the majority of patients. Adding
rituximab led to complete remission in 46% of the patients.41
Optimal dose of rituximab and duration
of treatment
Theoptimal rituximabdose inAIHAandother autoimmune cytopenias
has not been established. Initially, rituximab was used following the
classical lymphomaprotocol, consisting of 4weekly doses of 375mg/m2
per week.42 However, given the fact that the amount of B cells in
a disturbed immune system is considerably lower compared with the
high malignant B-cell burden in most lymphoproliferative B-cell
disorders, lower doses of rituximab have been explored in the treatment
of autoimmune cytopenias, especially in ITP. In a recently published
prospective trial, Barcellini et al23 investigated the use of low-dose
rituximab in 24 patients with warm- and cold-type AIHA. Rituximab
was given in a ﬁxed dose of 100 mg/week for 4 consecutive weeks.
Overall response rate and relapse-free survival (RFS) at 12monthswere
both 100% in the warm type, with an estimated RFS at 2 years of 81%.
An update of this study with longer follow-up conﬁrmed the high
sustained response rates with RFS in the whole group of 68% at 36
months.43 However, in the recently published GIMEMA study (that
probably included the patients previously presented byBarcellini et al),
the relapse rate of patients treated with low-dose rituximab (6 of 16)
was signiﬁcantly superior to the relapse rate observed after full-dose
rituximab (2 of 42).2 In ITP, 2 trials have been conductedwith low-dose
rituximab, showing that the level and duration of B-cell depletion and
the response rates seemed similar to cases treated with conventional
dose of rituximab, although responses may be less durable.44,45
Response duration in patients with AIHA is very variable, with a
median response of;1 year, although a very wide range is observed.
Recent studies with longer follow-up show that responses up to 3 years
are sustained in a proportion of patients (up to 30%).26,43 Whether
some patients can be considered cured after rituximab administration
is not clear, given the lack of long-term follow-up in most published
series. Maintenance therapy with rituximab aiming to prolong dura-
tion of response has not been investigated in this setting. As a substan-
tial fraction of patients beneﬁts from a prolonged response after a ﬁrst
treatment with rituximab, maintenance assessment should better con-
centrate on relapsing patients unless the wAIHA occurs as a compli-
cation of an underlying condition known to beneﬁt from maintenance
with rituximab. Patientswho, after successful treatmentwith rituximab,
maintain a response at the price of prolonged low-dose steroids or other
immunosuppressive treatments, or who poorly tolerate such a pro-
longed treatment, are also candidates for assessment of rituximab
maintenance.
Should rituximab be used up front in patients
with wAIHA?
Two recent prospective studies have conﬁrmed the value of rituximab
as ﬁrst-line treatment. Barcellini et al43 treated 8 newly diagnosed
patients with a ﬁxed dose of rituximab of 100 mg for 4 weekly
infusions. However, interpretation of responses is difﬁcult given the
low number of patients and the mixture of cases with wAIHA and
CAD. More information is obtained from the ﬁrst prospective
randomized phase 3 trial conducted in Denmark, including 64 patients
with newly diagnosed wAIHA.46 Following inclusion, patients
were randomized to receive prednisolone with or without rituximab
375mg/m2perweek for 4 consecutiveweeks.Combination therapywas
associated with an increased response rate (75% vs 36% at 12 months)
anda longer relapse-free survival (70%vs45%at36months) compared
with monotherapy with steroids, without additional adverse events. As
any clinical study, the Danish work has its limitations: the number of
patients included in this study (32 in each arm) is relatively low, even if
few clinical studies could accrue 64 patients with wAIHA and even if
this is compensated to a large extent by the magnitude of the beneﬁt in
favor of patients given rituximab. The poor accessibility to rituximab as
ﬁrst-line therapy in this indicationmay limit its widespread use inmany
countries. In addition, some objectives of the study could not bemet. In
particular, there was no reduction in blood transfusion need or in the
number of splenectomies in favor of patients assigned to rituximab.
This provocative study should encourage additional clinical trials
aimed at conﬁrming the data, at identifying the patients who beneﬁt
from an early use of monoclonal antibodies, and at assessing if upfront
rituximab could have a steroid-sparing effect, as similar doses of
steroids were given in both arms of the Danish study. This point
is particularly relevant as adult patients with wAIHA are relatively
old (39% were$65 years of age in the GIMEMA study), and as co-
morbidities are commonlyassociatedwithwAIHA.A longer follow-up
of the patients accrued in the Danish study showing that the beneﬁt
in favor of rituximab is maintained over time could also contribute to
modify our ﬁrst-line treatment policy in wAIHA. Meanwhile, upfront
use of rituximab could be considered in patientswhoprove intolerant to
steroids. The Danish data do not support the use of rituximab as an
emergency treatment of severe cases of wAIHA, as the response rate of
patients givenupfront rituximab is not increasedwith respect to controls
given steroids alone during the ﬁrst 3 months of treatment.
Splenectomy or rituximab?
Although wAIHA is a chronic disorder, not all patients will need a
second-line treatment. In a large French hospital a second-line therapy
was given in 56% of 60 patients and in the GIMEMA study in 40%
of 174 patients.2,37 In both studies, the proportion of patients offered
a splenectomy was relatively low: in the French study, only 9 patients
(15%) underwent splenectomy, whereas 28 (46.5%) patients were
given rituximab at some stage of the disease. In the GIMEMA study,
26 patients with wAIHA (15%) underwent splenectomy, whereas 32
(18%) received rituximab. Whether the relatively low proportion of
patients offered a splenectomy in both studies results from the use
of rituximab is unknown because the proportion of patients with
wAIHAundergoing splenectomy before the advent of rituximab has
been poorly assessed. Of note, only 2 patients in the rituximab era
underwent splenectomy after failure of ﬁrst-line steroids (vs 19 who
3226 DIERICKX et al BLOOD, 21 MAY 2015 x VOLUME 125, NUMBER 21
For personal use only.on May 22, 2015. by guest  www.bloodjournal.orgFrom 
were treatedwith rituximab), whereas 7were offered splenectomy at
a later stage of the disease,which suggests that therapywith rituximab
prior to (or instead of) splenectomy tends to become the standard of
care, at least in that large French hospital.
Response rates to splenectomy and to rituximab seem equivalent
even if no prospective study is available comparing the success rates
of both approaches. In the French study, 9 patients underwent sple-
nectomy: 6 achieved complete response (CR) and 3 achieved a partial
response (PR). In the same study, 20 of 25 patients given rituximab
achieved a PR or CR. Similar response rates were found in the
GIMEMA study: of 26 patients offered a splenectomy, 20 (77%) re-
sponded (19 CRs and 1 PR) compared with 26 of 32 (81%) patients
treated with rituximab, including 17 CRs and 9 PRs.
Duration of response between both therapeutic options does not
seem very different. Splenectomy is associated with a 67% long-term
response and a cure rate of;20%.1 These numbers seem to be identi-
cal to the results obtained with rituximab, taking into account that
(even often repeated) retreatment in patients previously responding
to rituximab is associated with a similar response in the majority of
patients.1,24
Does a previous splenectomy impact on the
probability of response to subsequent
treatment with rituximab?
We compared the published response rates in patients given rituximab
after failure of splenectomy to response rates after rituximab in patients
with an intact spleen. Single case reports and studies with a mixture
of ITP and AIHA cases or with a mixture of CAD and wAIHA cases
thatwere analyzed as a single entitywere excluded. In 44 patients given
rituximab after failure of splenectomy, 22 (50%) achieved a CR, 12
(27%) a PR, and 10 (23%) failed.25,32,36,45,47-56 In 128 patients from
the same studies, who were given rituximab and did not have a previ-
ous splenectomy, 82 (64%) achieved a CR, 30 (23.5%) a PR, and 16
(12.5%) failed. The difference is not signiﬁcant (P5 .17; x2 test).With
all the limitations of such an aggregate of heterogeneous studies,
this suggests that the beneﬁt from rituximab is not substantially com-
promised by a previous splenectomy. Conversely, the impact of previ-
ous treatment with rituximab on the success rate of splenectomy is
unknown because of the very few reported cases.
Adverse effects from splenectomy and
from rituximab
Splenectomy-related morbidity and mortality have been decreasing
during the last decades, probably as a consequence of systematic
preoperative vaccination, prevention of thrombosis, and widespread
use of laparoscopic splenectomy. The incidence of postsplenectomy
venous and arterial thrombotic events has recently been described in
more detail. In the GIMEMA study, a thrombotic event was recorded
in 11%of 308patientswithwAIHAandCAD, including11pulmonary
embolisms and 13 deep vein thromboses.2 Thrombotic events were
more frequent in patients who had undergone splenectomy (24% vs
8.7%). Surprisingly, the presence of a lupus anticoagulant or of anti-
cardiolipin antibodies (present in 13% of patients) was not associated
with an increased risk of thrombosis. In the same study, grade 3
pulmonary infections were associated with splenectomy but not with
the number of lines of treatment or with the use of rituximab.
Progressive multifocal leukoencephalopathy remains a major concern
in patients given rituximab. In a series of 57HIV-negative patients who
developed progressive multifocal leukoencephalopathy after treat-
mentwith rituximab, 2 hadbeengiven rituximab to treat an autoimmune
hemolysis associatedwith a lymphoproliferative disorder, including one
with previous stem cell transplantation and a second one treated only
with steroids and rituximab.57 Reactivation of hepatitis B infection
should be prevented by antiviral prophylaxis.58
Overall, rituximab was recommended as a second-line therapy by
the GIMEMA group.2 However, the decision remains a difﬁcult one
and is better made on the basis of individual considerations, taking
into account operative risk, probability of thrombosis, availability of
rituximab, and patient preferences.
What after rituximab failure?
Patients resistant to rituximab have been poorly studied. From the
Belgian study, it can be suspected that resistance to rituximab is as-
sociated with a poor outcome: of 12 such patients with ITP, CAD, and
wAIHA, 2 obtained aCRand 3 a PRwith another treatment, 4were left
untreated, and 3 died of infectious complications.25 Prognosis after
relapse from a previous successful treatment with rituximab is much
better, asmost relapsing patients will respond again to rituximab. Of 34
relapsing patients reported outside single case reports, 32 responded
again to rituximab.26,32,36,37,54 Of note, reminiscent of thrombopoietin
agonists in immune thrombocytopenic purpura, some patients seem
to respond to erythropoietin. In the GIMEMA study, 13 of 14 patients
with AIHA responded to treatment with erythropoietin but were given
concomitant various therapies, which precludes any convincing
conclusion.2
What can be concluded from the
available evidence?
Rituximab has enlarged our therapeutic repertoire in AIHA. The most
appropriate use of rituximab remains, however, to be deﬁned, es-
pecially the dose, the timing of treatment, and its position compared
with established treatments including splenectomy. The available data,
although consistently reporting some efﬁcacy of rituximab in wAIHA,
are far from robust: practically all the published studies are ret-
rospective, with poorly deﬁned criteria of inclusion, heterogeneous
criteria for response, admixture of primary and secondary cases,
variable rituximab dose, and number of cycles. TheDanish prospective
study is a remarkable exception.46 The Danish investigators demon-
strate that randomized studies aimed at deﬁning the role of rituximab in
wAIHA are feasible even in relatively small countries. However, at this
time, such studies remain desperately few: 9 studies can be identiﬁed
on clinicaltrials.gov with the use of “rituximab AND autoimmune
hemolytic anemia” key words. Only 3 are randomized phase 3 studies,
and none are open for recruitment.
Meanwhile, we cannot afford to ignore the use of rituximab in
wAIHA and we need to rely on reasonable conclusions from available
clinical data.
Obviously, upfront treatment with rituximab is reasonable in the
rare patients with wAIHA secondary to a disorder requiring an anti-
CD20 antibody, such as severe forms of low-grade lymphoma and
chronic lymphocytic leukemia. Patients with a contraindication to
steroids could also beneﬁt from ﬁrst-line rituximab. In patients
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relapsing after or refractory to steroids, splenectomy remains a
valid option. However, rituximab is an alternative that seems to gain
wider acceptance, especially in patients at high risk for surgery or
who elect not to undergo surgery as illustrated by the increasing
number of published patient series during the last years (Table 1).
Response rates do not differ signiﬁcantly from those observed after
splenectomy but response duration may be shorter. However,
several courses of rituximab can be administered with success after
relapse.
More experience, especially longer follow-up after treatment with
low-dose rituximab, is needed before it can be recommended in
everyday practice. Maintenance with rituximab should be assessed in
autoimmune disorders such as AIHA, especially in relapsing patients,
because the underlying immunological disorder persists in most
patients even after successful treatment, irrespective of its nature.
Finally, as clinical trials are developing in the ﬁeld of autoimmune
hemolytic anemia, especially since the introduction of monoclonal
antibodies, consensual deﬁnitions of responses to therapy should be
implemented to allow valid comparisons between studies.
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